Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
about
Effects of Metformin on Tissue Oxidative and Dicarbonyl Stress in Transgenic Spontaneously Hypertensive Rats Expressing Human C-Reactive ProteinFibrates for primary prevention of cardiovascular disease events.Acute Effect of Metformin on Postprandial Hypertriglyceridemia through Delayed Gastric EmptyingEffects of fibrates on C-reactive protein concentrations: a meta-analysis of randomized controlled trials.Possible role of interleukin-1β in type 2 diabetes onset and implications for anti-inflammatory therapy strategies.Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes.The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemiaShort-term effect of fenofibrate on C-reactive protein: A meta-analysis of randomized controlled trials.Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats.Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.Fenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: an open-label interventional study.Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review.New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser.Fibrates in the management of atherogenic dyslipidemia.Haemostatic effects of metformin in simvastatin-treated volunteers with impaired fasting glucose.Effect of bezafibrate on monocyte cytokine release and systemic inflammation in patients with impaired fasting glucose.Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial.
P2860
Q28550686-BAABAE98-9A28-40A5-86AD-EBC79E198990Q30241199-B4283D1D-645F-4EAB-8A5B-6733BA6944D6Q33839003-BE83E9D3-D12E-4A91-BED0-2216302FA6DFQ34068794-ADB8AB5A-5A26-4D08-993C-9C3FCE055E81Q34104455-D68DF245-2AC0-47CC-BC49-7FD7F579A7A9Q34153553-CAC198D0-8C42-4B89-9E35-84BD18C910B5Q35332645-BC221AE2-E7E2-46FA-814C-B1BE65A70780Q35386431-E6C4881A-54FB-418F-872B-859C522742ADQ37064893-FA5F71DE-392A-4C3E-8749-F9E9AED14ECCQ37653029-A8C38D92-65BE-4044-8A74-37C633D96D77Q37681585-793A9567-8212-427E-8C47-A3F7421C2BBEQ37964751-3C48D1C2-A0E7-4921-A4B7-5502A6E2DEE9Q39626084-5F2643AA-5A64-42D2-81CA-1C7429E70AD8Q49571281-28F7D1E3-3C65-470C-8B69-7CBFD6BFDB65Q51355302-1FFE26C0-2908-4627-A592-57DAF7F2F756Q51385582-34BA83A5-160D-4A22-965E-CE44373B2A32Q55400264-EC95B07C-C8D5-4BE7-A4B2-DCD65B9F3820
P2860
Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Pleiotropic action of short-te ...... ients with mixed dyslipidemia.
@en
Pleiotropic action of short-te ...... ients with mixed dyslipidemia.
@nl
type
label
Pleiotropic action of short-te ...... ients with mixed dyslipidemia.
@en
Pleiotropic action of short-te ...... ients with mixed dyslipidemia.
@nl
prefLabel
Pleiotropic action of short-te ...... ients with mixed dyslipidemia.
@en
Pleiotropic action of short-te ...... ients with mixed dyslipidemia.
@nl
P2093
P2860
P356
P1433
P1476
Pleiotropic action of short-te ...... ients with mixed dyslipidemia.
@en
P2093
Boguslaw Okopien
Maciej Pruski
Robert Krysiak
P2860
P304
P356
10.2337/DC08-2335
P407
P577
2009-05-12T00:00:00Z